News

Promising Phase 1Trial on POL6014 for Cystic Fibrosis Finished

Swiss Pharmaceutical company Polyphor has successfully completed its Phase I clinical trial in healthy volunteers for the investigational inhaled POL6014. POL6014 is a selective and reversible inhibitor of human neutrophil elastase (hNE), a key target for the treatment of respiratory diseases like cystic fibrosis (CF). Cystic fibrosis is a genetic…

Healthcare Workers with CF Prone to MRSA, Study Shows

Healthcare workers with cystic fibrosis (CF) are more likely to contract methicillin-resistant staphylococcus aureus (MRSA) infections than CF patients not in healthcare scenarios, according to the study “Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study,” published in BMC Pulmonary Medicine. MRSA infection is caused…

PTC Therapeutics Announces Winners of 2016 STRIVE Awards for CF

PTC Therapeutics, Inc. recently announced the recipients of its global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, which supports nonprofit associations assisting the cystic fibrosis (CF) community. The STRIVE Program recognizes the vital role patient advocacy groups play in giving voice to individuals affected by these rare…